Partnerships for Development and Commercialisation of Novel Class of Protein Drugs


Client

German Biotech company making safer, effective and differentiated Novel drugs

Client Need

Innovator partners to collaborate on a new class of  proteins - Anticalins® to develop various programs in Oncology and Ophthalmology. 

Solution Approach

  • Aagami identified right partners, and took them to 7 interested companies for Anticalins®
  • With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations. 
  • Aagami maintained its spirits and perseverance knowing business and socio-cultural differences of various countries/regions; even when client was ready to give up as per their ways. 
  • Finally co development partnership happened in next few months with one company in Oncology.
  • Second company took more time and couple of visits  before  signing co-development deal  for ophthalmic therapy.

Results

  • Client signed co-development deals with 2 companies in Oct and Dec 2013 respectively.
  • Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen. 
  • Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of various geographies.
  • It brought repeat  and referral business to Aagami.

Downloadable Version:

Aagami Case Study - Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs from Aagami, Inc.
×
Twitter